|
US7655699B1
(en)
|
1992-04-22 |
2010-02-02 |
Eisai Inc. |
Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
|
|
GB9222253D0
(en)
*
|
1992-10-23 |
1992-12-09 |
Celltech Ltd |
Chemical compounds
|
|
GB9304919D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
|
GB9304920D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
|
DE69433594T2
(de)
*
|
1993-12-22 |
2004-08-05 |
Celltech R&D Ltd., Slough |
Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
|
|
US6245774B1
(en)
|
1994-06-21 |
2001-06-12 |
Celltech Therapeutics Limited |
Tri-substituted phenyl or pyridine derivatives
|
|
US6942980B1
(en)
*
|
1995-09-01 |
2005-09-13 |
Allergan, Inc. |
Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
|
|
US5958954A
(en)
*
|
1995-09-01 |
1999-09-28 |
Allergan Sales, Inc. |
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
|
|
GB9523675D0
(en)
*
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9526245D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9526243D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
US5877207A
(en)
*
|
1996-03-11 |
1999-03-02 |
Allergan Sales, Inc. |
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
|
|
WO1997034869A1
(en)
*
|
1996-03-18 |
1997-09-25 |
Eisai Co., Ltd. |
Fused-ring carboxylic acid derivatives
|
|
GB9608435D0
(en)
*
|
1996-04-24 |
1996-06-26 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
US6555690B2
(en)
*
|
1996-06-21 |
2003-04-29 |
Allergan, Inc. |
Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
|
|
DE69728986T2
(de)
*
|
1996-06-21 |
2005-04-07 |
Allergan, Inc., Irvine |
Substituierte tetrahydronaphthalin- und dihydronaphthalin-derivate mit einer retinoiden und/oder retinoid antagonist-ähnlichen biologischen aktivität
|
|
US5773594A
(en)
|
1996-06-21 |
1998-06-30 |
Allergan |
Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
|
|
GB9619284D0
(en)
*
|
1996-09-16 |
1996-10-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9622363D0
(en)
*
|
1996-10-28 |
1997-01-08 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9625184D0
(en)
*
|
1996-12-04 |
1997-01-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
US6057329A
(en)
*
|
1996-12-23 |
2000-05-02 |
Celltech Therapeutics Limited |
Fused polycyclic 2-aminopyrimidine derivatives
|
|
US5760276A
(en)
*
|
1997-03-06 |
1998-06-02 |
Allergan |
Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
|
|
AU6955898A
(en)
*
|
1997-04-11 |
1998-11-11 |
Bristol-Myers Squibb Company |
Retinoid antagonists and uses thereof
|
|
AU749810B2
(en)
*
|
1997-11-12 |
2002-07-04 |
Basilea Pharmaceutica Ag |
Treatment of T-helper cell type 2 mediated immune diseases
|
|
IL142094A0
(en)
*
|
1998-09-29 |
2002-03-10 |
Gamida Cell Ltd |
Methods of controlling proliferation and differentiation of stem and progenitor cells
|
|
US6403638B1
(en)
|
1998-10-01 |
2002-06-11 |
Allergan Sales, Inc. |
2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
|
|
US6048873A
(en)
*
|
1998-10-01 |
2000-04-11 |
Allergan Sales, Inc. |
Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
|
|
US6147224A
(en)
*
|
1998-10-01 |
2000-11-14 |
Allergan Sales, Inc. |
2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
|
|
ATE289507T1
(de)
*
|
1998-10-08 |
2005-03-15 |
Allergan Inc |
Rar-antagonisten zur verhütung für männer
|
|
US6521641B1
(en)
*
|
1998-10-08 |
2003-02-18 |
Allergan, Inc. |
Male anti-fertility agents
|
|
AU1229000A
(en)
*
|
1998-10-23 |
2000-05-15 |
Glaxo Group Limited |
Assays for ligands for nuclear receptors
|
|
US6326397B1
(en)
|
1998-11-10 |
2001-12-04 |
Hoffman-La Roche Inc. |
Retinoid antagonists and use thereof
|
|
US6054623A
(en)
*
|
1998-12-18 |
2000-04-25 |
Alliedsignal Inc. |
Hydroxythiol grignard reaction synthesis
|
|
CA2366186C
(en)
*
|
1999-03-08 |
2007-05-15 |
Basilea Pharmaceutica Ag |
Retinoid antagonists and use thereof
|
|
WO2000061232A2
(en)
*
|
1999-04-14 |
2000-10-19 |
Allergan Sales, Inc. |
Methods and compositions for the treatment and prevention of lung disease involving a specific rar-beta antagonist
|
|
AU4228000A
(en)
*
|
1999-04-14 |
2000-11-14 |
Allergan Sales, Inc. |
Methods and compositions for the treatment and prevention of lung disease
|
|
WO2000066595A1
(en)
|
1999-04-28 |
2000-11-09 |
Institute Of Medicinal Molecular Design. Inc. |
Heterocyclic carboxylic acid derivatives
|
|
HK1047752A1
(zh)
|
1999-06-11 |
2003-03-07 |
Allergan, Inc. |
具有核激素受体调节活性的有机硅化合物
|
|
US6906057B1
(en)
|
1999-06-11 |
2005-06-14 |
Allergan, Inc. |
Methods for modulating FXR receptor activity
|
|
CN1391576A
(zh)
|
1999-08-27 |
2003-01-15 |
利甘德药品公司 |
雄激素受体调节剂化合物及方法
|
|
AU6941200A
(en)
|
1999-08-27 |
2001-03-26 |
Ligand Pharmaceuticals Incorporated |
8-substituted-6-trifluoromethyl-9-pyrido(3,2-g)quinoline compounds as androgen receptor modulators
|
|
US6566372B1
(en)
*
|
1999-08-27 |
2003-05-20 |
Ligand Pharmaceuticals Incorporated |
Bicyclic androgen and progesterone receptor modulator compounds and methods
|
|
CA2383565A1
(en)
*
|
1999-09-14 |
2001-03-22 |
Ligand Pharmaceuticals Incorporated |
Rxr modulators with improved pharmacologic profile
|
|
US6313168B1
(en)
*
|
1999-12-15 |
2001-11-06 |
Allergan Sales, Inc. |
Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
|
|
US20030114482A1
(en)
*
|
1999-12-15 |
2003-06-19 |
Maurizio Pacifici |
Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
|
|
US6713515B2
(en)
|
2000-09-13 |
2004-03-30 |
Bristol Myers Squibb Company |
Retinoic acid receptor antagonists as promoters of angiogenesis
|
|
US20030003517A1
(en)
*
|
2001-03-22 |
2003-01-02 |
Klein Elliott S. |
Methods of detecting dissociated nuclear hormone receptor ligands
|
|
US20020193403A1
(en)
*
|
2001-05-03 |
2002-12-19 |
Allergan Sales, Inc. |
Methods of treating hyperlipidemia
|
|
MEP13408A
(en)
|
2001-05-29 |
2010-06-10 |
Bayer Schering Pharma Ag |
Cdk inhibiting pyrimidines, production thereof and their use as medicaments
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
US7998986B2
(en)
|
2001-12-21 |
2011-08-16 |
Exelixis Patent Company Llc |
Modulators of LXR
|
|
IL152904A0
(en)
*
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
|
WO2003062404A1
(en)
|
2002-01-25 |
2003-07-31 |
Gamida-Cell Ltd. |
Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
|
|
EP1532273A4
(en)
*
|
2002-06-20 |
2009-11-18 |
Primera Biosystems Inc |
DEVICE FOR DETECTING AND QUANTIFYING POLYNUCLEOTIDES
|
|
AU2003249534A1
(en)
*
|
2002-08-13 |
2004-02-25 |
Warner-Lambert Company Llc |
6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
|
|
US7105566B2
(en)
*
|
2002-10-22 |
2006-09-12 |
Allergan, Inc. |
Methods of treatment during vascular procedures
|
|
FR2847255B1
(fr)
*
|
2002-11-18 |
2006-11-17 |
Galderma Res & Dev |
Nouveaux ligands antagonistes des recepteurs rars, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
|
|
ES2283866T3
(es)
*
|
2002-11-18 |
2007-11-01 |
GALDERMA RESEARCH & DEVELOPMENT |
Nuevos ligandos que son antagonistas de los receptores rar, procedimiento de preparacion de estos ligandos y utilizacion de estos ligandos en el campo de la medicina humana y de la cosmetica.
|
|
US20050026958A1
(en)
*
|
2003-07-30 |
2005-02-03 |
Allergan, Inc. |
Methods of therapeutic treatment using amounts of retinoid components
|
|
US20050026951A1
(en)
*
|
2003-07-30 |
2005-02-03 |
Allergan, Inc. |
Methods of therapeutic treatment using retinoids with reduced drug interaction
|
|
US20050026950A1
(en)
*
|
2003-07-30 |
2005-02-03 |
Allergan, Inc. |
Methods of therapeutic treatment using retinoids to achieve consistent bioavailability
|
|
US20050026949A1
(en)
*
|
2003-07-30 |
2005-02-03 |
Allergan, Inc. |
Methods of therapeutic treatment using amounts of retinoids without regard to body weight
|
|
US20050101582A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
|
US20060141049A1
(en)
*
|
2003-11-12 |
2006-06-29 |
Allergan, Inc. |
Triamcinolone compositions for intravitreal administration to treat ocular conditions
|
|
US20070224278A1
(en)
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
|
MXPA06007255A
(es)
*
|
2003-12-26 |
2006-08-18 |
Allergan Inc |
Oximas de chalcona disubstituidas que tienen actividad antagonista de los receptores retinoides rar?.
|
|
JP2007518804A
(ja)
|
2004-01-20 |
2007-07-12 |
アラーガン、インコーポレイテッド |
トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
|
|
US20050244462A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
|
US8119154B2
(en)
*
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
|
US8425929B2
(en)
*
|
2004-04-30 |
2013-04-23 |
Allergan, Inc. |
Sustained release intraocular implants and methods for preventing retinal dysfunction
|
|
US8455656B2
(en)
|
2004-04-30 |
2013-06-04 |
Allergan, Inc. |
Kinase inhibitors
|
|
US20050244471A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
|
US7993634B2
(en)
|
2004-04-30 |
2011-08-09 |
Allergan, Inc. |
Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
|
|
US20050244478A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Anti-excititoxic sustained release intraocular implants and related methods
|
|
US7799336B2
(en)
|
2004-04-30 |
2010-09-21 |
Allergan, Inc. |
Hypotensive lipid-containing biodegradable intraocular implants and related methods
|
|
US20050244458A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular neuropathies
|
|
WO2005107708A1
(en)
|
2004-04-30 |
2005-11-17 |
Allergan, Inc. |
Biodegradable intravitreal tyrosine kinase inhibitors implants
|
|
US8147865B2
(en)
*
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
|
US8673341B2
(en)
|
2004-04-30 |
2014-03-18 |
Allergan, Inc. |
Intraocular pressure reduction with intracameral bimatoprost implants
|
|
US20050244463A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Sustained release intraocular implants and methods for treating ocular vasculopathies
|
|
US20050244461A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Controlled release drug delivery systems and methods for treatment of an eye
|
|
US20050244465A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Drug delivery systems and methods for treatment of an eye
|
|
US7771742B2
(en)
|
2004-04-30 |
2010-08-10 |
Allergan, Inc. |
Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
|
|
WO2005110374A1
(en)
*
|
2004-04-30 |
2005-11-24 |
Allergan, Inc. |
Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
|
|
US8591885B2
(en)
*
|
2004-04-30 |
2013-11-26 |
Allergan, Inc. |
Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
|
|
US20070059336A1
(en)
*
|
2004-04-30 |
2007-03-15 |
Allergan, Inc. |
Anti-angiogenic sustained release intraocular implants and related methods
|
|
US20050244466A1
(en)
*
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Photodynamic therapy in conjunction with intraocular implants
|
|
US8722097B2
(en)
|
2004-04-30 |
2014-05-13 |
Allergan, Inc. |
Oil-in-water method for making polymeric implants containing a hypotensive lipid
|
|
US9498457B2
(en)
|
2004-04-30 |
2016-11-22 |
Allergan, Inc. |
Hypotensive prostamide-containing biodegradable intraocular implants and related implants
|
|
US20060009498A1
(en)
*
|
2004-07-12 |
2006-01-12 |
Allergan, Inc. |
Ophthalmic compositions and methods for treating ophthalmic conditions
|
|
EP1621191A1
(en)
*
|
2004-07-29 |
2006-02-01 |
Werner Bollag |
Treatment of inflammatory diseases by RXR Antagonists
|
|
EP1799812A4
(en)
|
2004-09-16 |
2009-09-09 |
Gamida Cell Ltd |
EX VIVO CULTIVATION METHODS OF STEM CELLS AND PRECURSOR BY CO-CULTURE WITH MESENCHYMAL CELLS
|
|
WO2006043965A1
(en)
*
|
2004-10-14 |
2006-04-27 |
Allergan, Inc. |
Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
|
|
EP1937244B1
(en)
|
2005-09-30 |
2018-07-25 |
Io Therapeutics, LLC |
Treatment of cancer with specific rxr agonists
|
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
|
DK2026778T3
(en)
*
|
2006-05-16 |
2019-01-07 |
Io Therapeutics Llc |
RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND / OR RADIATION THERAPY SIDE EFFECTS
|
|
US8969415B2
(en)
|
2006-12-01 |
2015-03-03 |
Allergan, Inc. |
Intraocular drug delivery systems
|
|
CN101742916B
(zh)
*
|
2007-02-28 |
2015-08-19 |
肯塔基大学研究基金会 |
减轻视黄酸治疗副作用和/或改进疗效而不干扰疗效的方法
|
|
US7911053B2
(en)
*
|
2007-04-19 |
2011-03-22 |
Marvell World Trade Ltd. |
Semiconductor packaging with internal wiring bus
|
|
US8082730B2
(en)
*
|
2008-05-20 |
2011-12-27 |
Caterpillar Inc. |
Engine system having particulate reduction device and method
|
|
KR101041281B1
(ko)
*
|
2009-05-18 |
2011-06-14 |
주식회사 니프코코리아 |
자동차의 에어벤트 다이얼
|
|
BR112012010983A2
(pt)
|
2009-11-09 |
2016-04-12 |
Allergan Inc |
composições e métodos para a estimulação do crescimento de cabelos
|
|
CA2838179A1
(en)
|
2011-06-03 |
2012-12-06 |
Allergan, Inc. |
Targeted delivery of retinoid compounds to the sebaceous glands
|
|
AU2012352149B2
(en)
|
2011-12-13 |
2017-06-01 |
Io Therapeutics, Inc. |
Autoimmune disorder treatment using RXR agonists
|
|
US10653650B2
(en)
|
2011-12-13 |
2020-05-19 |
Io Therapeutics, Inc. |
Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
|
|
HK1202581A1
(en)
|
2012-02-13 |
2015-10-02 |
Gamida-Cell Ltd. |
Mesenchymal stem cells conditioned medium and methods of generating and using the same
|
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
|
US20140094512A1
(en)
|
2012-10-02 |
2014-04-03 |
Nikolas Gunkel |
Method of modulating the degree of adipose tissue deposited intramuscularly
|
|
CN109602691A
(zh)
|
2013-02-15 |
2019-04-12 |
阿勒根公司 |
持续药物递送植入物
|
|
CN108289958A
(zh)
|
2015-10-31 |
2018-07-17 |
Io治疗公司 |
使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
|
|
ES2898676T3
(es)
|
2015-11-25 |
2022-03-08 |
Io Therapeutics Inc |
Agonistas selectivos de rar-alfa resistentes a CYP26 en el tratamiento del cáncer
|
|
EA201891761A1
(ru)
*
|
2016-02-03 |
2019-01-31 |
Галдерма Ресерч Энд Девелопмент |
Новые биароматические соединения пропинила, фармацевтические и косметические композиции, их содержащие, и их применение
|
|
CN109310769B
(zh)
|
2016-03-10 |
2022-07-05 |
Io治疗公司 |
用rxr激动剂与甲状腺激素的组合的自身免疫疾病的治疗
|
|
KR20180121983A
(ko)
|
2016-03-10 |
2018-11-09 |
아이오 테라퓨틱스, 인크. |
Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 근육 질환의 치료
|
|
CN107176945B
(zh)
|
2016-03-11 |
2021-06-08 |
中国科学院上海有机化学研究所 |
一种视黄酸类化合物、其制备方法、中间体及应用
|
|
WO2017152725A1
(zh)
*
|
2016-03-11 |
2017-09-14 |
中国科学院上海有机化学研究所 |
一种视黄酸类化合物、其制备方法、中间体及应用
|
|
EP3468600A4
(en)
|
2016-06-10 |
2019-11-13 |
IO Therapeutics, Inc. |
RECEPTOR-ELECTIVE RETINOID AND REXINOID COMPOUNDS AND IMMUNOMODULATORS FOR CANCER IMMUNOTHERAPY
|
|
KR20200029543A
(ko)
|
2017-07-13 |
2020-03-18 |
아이오 테라퓨틱스, 인크. |
암 면역요법을 위해 면역 조절제와 조합된 수용체 서브타입 및 기능 선택적 레티노이드 및 렉시노이드 화합물
|
|
CN111148514A
(zh)
|
2017-08-31 |
2020-05-12 |
Io治疗公司 |
与免疫调节剂联合应用于癌症免疫治疗的rar选择性激动剂
|
|
WO2019060600A1
(en)
|
2017-09-20 |
2019-03-28 |
Io Therapeutics, Inc. |
TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS
|
|
US10966950B2
(en)
|
2019-06-11 |
2021-04-06 |
Io Therapeutics, Inc. |
Use of an RXR agonist in treating HER2+ cancers
|
|
MX2024006978A
(es)
|
2021-12-07 |
2024-07-19 |
Io Therapeutics Inc |
Uso de un agonista de rxr y taxanos en el tratamiento de cáncer her2+.
|
|
KR20240115316A
(ko)
|
2021-12-07 |
2024-07-25 |
아이오 테라퓨틱스, 인크. |
약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도
|